Thursday, 2 July 2009

Intersuisse: biotech back on the up (Thursday, 2 July 2009) THE Australian life science sector rebounded in the June quarter, gaining more than the All Ordinaries and the NASDAQ Biotechnology Index, according to Dr Darren Grubb from Intersuisse, in his quarterly report on the state of the listed life science sector. Full Story... More machinations at Progen (Thursday, 2 July 2009) PROGEN’S entire board has quit, in a surprise move that will throw shareholder attempts to spill the board into confusion. Full Story... Progen licenses PI-88 and other programs (Thursday, 2 July 2009) PROGEN has formalised the out-licence of liver cancer drug PI-88 to US-based Global TransBiotech, saying it will receive milestone payments of up to $5 million under the deal, as well as royalties if the drug makes it to market. Full Story... Neuren adds more army cash to clinical programs (Thursday, 2 July 2009) NEUREN has hit the top of the trading charts again, after announcing yesterday the company will receive additional money from the United States army for clinical trials of its neuroprotective drugs under development. Full Story... Bionomics targets US Phase 2 in renal cancer (Thursday, 2 July 2009) BIONOMICS plans to open a US Phase 2 trial in renal cancer as the next phase of development for its vascular disrupting agent BNC105. Full Story... NuSep takeover collapses (Thursday, 2 July 2009) NUSEP says its planned merger with NxGen has collapsed, following the failure of a $5 million capital raising exercise associated with the back-door listing of NxGen. Full Story... Unilife extends Sanofi deal (Thursday, 2 July 2009) SAFETY syringe company Unilife has extended its agreement with pharma major Sanofi-Aventis, extending the exclusivity period for Sanofi’s access to its pre-filled safety syringe and clarifying the Australian company’s right to market it to other pharma companies. Full Story... Parnell sells legacy assets to focus on new therapeutics (Thursday, 2 July 2009) SYDNEY-based veterinary pharmaceutical company Parnell Laboratories has sold the last of the company’s legacy pharma brands, as the company completes its shift in focus to the development of new animal therapeutic products. Full Story... Patent problems for GTG (Thursday, 2 July 2009) GENETIC Technologies may have patent problems, with the United States Patent and Trademark Office taking the first steps to rub out one of its key non-coding DNA patents. Full Story... Bio People: Avexa, Solagran, Tissue Therapies, NuSep and ITL (Thursday, 2 July 2009) THE last week of the financial year has been a busy one in life science boardrooms. In addition to sweeping changes at ChemGenex and Progen, a raft of other companies have been tinkering with their boardroom structure. Full Story... Another Euro approval for CathRx (Thursday, 2 July 2009) CARDIAC catheter manufacturer CathRx says the last of its diagnostic catheters has received CE mark approval with European regulators approving the marketing of its advanced diagnostic, or “loop” catheter. Full Story... Bio briefs: Safety Medical, Tissue Therapies, LCT and Anaeco (Thursday, 2 July 2009) SAFETY Medical Products says it has sold its printing assets, Bagot Press, for $1.3 million, with the sale proceeds to be used to grow its new feminine hygiene products business. Full Story...

Tuesday, 30 June 2009

Fermiscan dumps Polartechnics merger (Tuesday, 30 June 2009) DESPITE initially announcing their support for a proposed merger with Polartechnics, Fermiscan directors have back-tracked at a rate of knots over the last week, recommending shareholders reject the deal in a target statement released yesterday. Full Story... EnGeneIC "breakthrough" in Nature (Tuesday, 30 June 2009) SYDNEY biotechnology company EnGeneIC says a major publication in Nature Biotechnology next month validates its approach to developing cancer therapeutics. Full Story... ChemGenex quits NASDAQ, trims board (Tuesday, 30 June 2009) CHEMGENEX will quit its NASDAQ listing next month, citing the growing compliance costs and limited utility of the US tech exchange listing. Full Story... Phosphagenics clears another Phase 1 (Tuesday, 30 June 2009) PHOSPHAGENICS says a Phase 1 trial of its transdermal oxycodone delivery gel doesn’t appear to generate many of the side effects normally expected during the topical application of opiates. Full Story... Bio execs launch mentoring business (Tuesday, 30 June 2009) IT can be a lonely life as a biotech chief executive, according to former BioDiem CEO Tom Williams. Full Story... Stirling to acquire contract manufacturer (Tuesday, 30 June 2009) STIRLING Products is continuing its ambitious acquisition program, announcing late last week the company will add New South Wales contract manufacturing company MilPharma to its stable. Full Story... Capital Briefs: Patrys, Pharmaxis, ImpediMed and more (Tuesday, 30 June 2009) PATRYS has launched a $6.8 million renounceable pro rata rights issue to fund the clinical program for its natural human antibodies. Full Story... Bio Briefs: ASDM, Pharmanet, Iatia and more (Tuesday, 30 June 2009) ADVANCED Surgical Design and Manufacture has signed a US distributor for its orthopaedic implants, announcing that ANOVA Implant solutions will distribute its products. Full Story... Sirtex battle gets dirty (Tuesday, 30 June 2009) SIRTEX is warning shareholders to pay no attention to a “shit sheet” being circulated ahead of a showdown over company founder Dr Bruce Gray’s ongoing efforts to oust Richard Hill from the board. Full Story...

Monday, 29 June 2009

Market Pulse: recovery slows (Monday, 29 June 2009) IT was back to the doldrums for the biotech sector last week, as life science companies lost ground across the board. Despite a solid recent run, the majority of companies on BTN’s life science watchlist went backwards last week, with 69 falling, 39 rising and the rest remaining unchanged or untraded. Full Story...

Click here to read today's news stories.

Click here to read our complete archive.